These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
143 related items for PubMed ID: 1940775
1. Effect of apolipoprotein E polymorphism and XbaI polymorphism of apolipoprotein B on response to lovastatin treatment in familial and non-familial hypercholesterolaemia. Ojala JP, Helve E, Ehnholm C, Aalto-Setälä K, Kontula KK, Tikkanen MJ. J Intern Med; 1991 Nov; 230(5):397-405. PubMed ID: 1940775 [Abstract] [Full Text] [Related]
2. Serum low density lipoprotein cholesterol level and cholesterol absorption efficiency are influenced by apolipoprotein B and E polymorphism and by the FH-Helsinki mutation of the low density lipoprotein receptor gene in familial hypercholesterolemia. Gylling H, Aalto-Setälä K, Kontula K, Miettinen TA. Arterioscler Thromb; 1991 Nov; 11(5):1368-75. PubMed ID: 1911722 [Abstract] [Full Text] [Related]
5. The effect of the apolipoprotein E phenotype on cholesteryl ester transfer protein activity, plasma lipids and apolipoprotein A I levels in hypercholesterolaemic patients on colestipol and lovastatin treatment. Korhonen T, Hannuksela ML, Seppänen S, Kervinen K, Kesäniemi YA, Savolainen MJ. Eur J Clin Pharmacol; 1999 Feb; 54(12):903-10. PubMed ID: 10192749 [Abstract] [Full Text] [Related]
6. Comparison of lovastatin and probucol in treatment of familial and non-familial hypercholesterolemia: different effects on lipoprotein profiles. Helve E, Tikkanen MJ. Atherosclerosis; 1988 Aug; 72(2-3):189-97. PubMed ID: 3063268 [Abstract] [Full Text] [Related]
8. Heterozygous familial hypercholesterolaemia: the influence of the mutation type of the low-density-lipoprotein receptor gene and PvuII polymorphism of the normal allele on serum lipid levels and response to lovastatin treatment. Vuorio AF, Ojala JP, Sarna S, Turtola H, Tikkanen MJ, Kontula K. J Intern Med; 1995 Jan; 237(1):43-8. PubMed ID: 7830029 [Abstract] [Full Text] [Related]
10. Effect of apolipoprotein E genotype on lipid levels and response to diet in familial hypercholesterolemia. Carmena-Ramón R, Real JT, Ascaso JF, Ordovás JM, Carmena R. Nutr Metab Cardiovasc Dis; 2000 Feb; 10(1):7-13. PubMed ID: 10812582 [Abstract] [Full Text] [Related]
15. Phenotypic heterogeneity associated with defective apolipoprotein B-100 and occurrence of the familial hypercholesterolemia phenotype in the absence of an LDL-receptor defect within a Canadian kindred. Davignon J, Dufour R, Roy M, Bétard C, Ma Y, Ouellette S, Boulet L, Lussier-Cacan S. Eur J Epidemiol; 1992 May; 8 Suppl 1():10-7. PubMed ID: 1505645 [Abstract] [Full Text] [Related]
17. The effect of the apolipoprotein E polymorphism on lipid levels in patients with familial defective apolipoprotein B-100. Manke C, Schuster H, Keller C, Wolfram G. Clin Investig; 1993 Apr; 71(4):277-80. PubMed ID: 8471813 [Abstract] [Full Text] [Related]
19. Differences in the phenotype between children with familial defective apolipoprotein B-100 and familial hypercholesterolemia. Pimstone SN, Defesche JC, Clee SM, Bakker HD, Hayden MR, Kastelein JJ. Arterioscler Thromb Vasc Biol; 1997 May; 17(5):826-33. PubMed ID: 9157944 [Abstract] [Full Text] [Related]
20. [Lovastatin in the treatment of primary hypercholesterolemia]. Broda G, Rywik S, Chotkowska E, Bednarek M, Kuzmińska A, Polakowska M. Kardiol Pol; 1991 May; 35(8):84-9. PubMed ID: 1942761 [Abstract] [Full Text] [Related] Page: [Next] [New Search]